{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:07:42Z","timestamp":1792267662105,"version":"4.4.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ctrv.2025.102908","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T11:22:06Z","timestamp":1740741726000},"page":"102908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8451-3055","authenticated-orcid":false,"given":"Edoardogregorio","family":"Galli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-2158","authenticated-orcid":false,"given":"Giorgio","family":"Patelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Gri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mazzarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Sgrazzutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Saverio","family":"Belli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"De Carlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Vanzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-3514","authenticated-orcid":false,"given":"Katia","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.102908_b0005","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"161","key":"10.1016\/j.ctrv.2025.102908_b0010","first-page":"108","article-title":"Global, regionaland national burden of primary liver cancer by subtype","volume":"2022","author":"Rumgay","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ctrv.2025.102908_b0015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2025.102908_b0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000339016","article-title":"Epidemiology and surveillance of hepatocellular carcinoma","volume":"1","author":"Kim","year":"2012","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0025","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2025.102908_b0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.ctrv.2025.102908_b0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2025.102908_b0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"Llovet","year":"2021","journal-title":"Hepatocellular carcinoma Nat Rev Dis Primer"},{"key":"10.1016\/j.ctrv.2025.102908_b0045","doi-asserted-by":"crossref","unstructured":"Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2018;29:iv238\u201355. DOI: 10.1093\/annonc\/mdy308.","DOI":"10.1093\/annonc\/mdy308"},{"key":"10.1016\/j.ctrv.2025.102908_b0050","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3350\/cmh.2020.0016","article-title":"Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients","volume":"26","author":"Kim","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ctrv.2025.102908_b0055","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1245\/s10434-020-08452-3","article-title":"Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria","volume":"27","author":"Tsilimigras","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0060","doi-asserted-by":"crossref","unstructured":"de\u2019Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol 2015;21:11185\u201398. DOI: 10.3748\/wjg.v21.i39.11185.","DOI":"10.3748\/wjg.v21.i39.11185"},{"key":"10.1016\/j.ctrv.2025.102908_b0065","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.3390\/cancers14205114","article-title":"Hepatocellular Carcinoma Recurrence and Mortality Rate Post Liver Transplantation: Meta-Analysis and Systematic Review of Real-World Evidence","volume":"14","author":"Bzeizi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2025.102908_b0070","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182\u2013236. DOI: 10.1016\/j.jhep.2018.03.019.","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"10.1016\/j.ctrv.2025.102908_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.763790","article-title":"Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.ctrv.2025.102908_b0085","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s12029-020-00486-w","article-title":"The Importance of AFP in Liver Transplantation for HCC","volume":"51","author":"\u00d6zdemir","year":"2020","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2482-14-40","article-title":"Effect of pre- and post-treatment \u03b1-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study","volume":"14","author":"Toro","year":"2014","journal-title":"BMC Surg"},{"key":"10.1016\/j.ctrv.2025.102908_b0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1089-3261(05)70158-6","article-title":"The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma","volume":"5","author":"Johnson","year":"2001","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ctrv.2025.102908_b0100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1478-3231.2010.02368.x","article-title":"Early \u03b1-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma","volume":"31","author":"Kim","year":"2011","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.ctrv.2025.102908_b0105","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0110","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2025.102908_b0115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-021-01089-z","article-title":"Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer","volume":"14","author":"Chen","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0120","doi-asserted-by":"crossref","DOI":"10.1088\/1478-3975\/9\/1\/010301","article-title":"A fluid biopsy as investigating technology for the fluid phase of solid tumors","volume":"9","author":"Kuhn","year":"2012","journal-title":"Phys Biol"},{"key":"10.1016\/j.ctrv.2025.102908_b0125","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0130","doi-asserted-by":"crossref","first-page":"10644","DOI":"10.3390\/ijms241310644","article-title":"Liquid Biopsy in Hepatocellular Carcinoma: The Significance of Circulating Tumor Cells in Diagnosis, Prognosis, and Treatment Monitoring","volume":"24","author":"Shaik","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.102908_b0135","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep4.1823","article-title":"Current and Emerging Tools for Hepatocellular Carcinoma Surveillance","volume":"5","author":"Adeniji","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ctrv.2025.102908_b0140","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2025.102908_b0145","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1016\/j.transproceed.2006.10.067","article-title":"Alpha-fetoprotein mRNA detection in peripheral blood for prediction of hepatocellular carcinoma recurrence after liver transplantation","volume":"38","author":"Marubashi","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ctrv.2025.102908_b0150","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/jhep.2002.32100","article-title":"alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study","volume":"35","author":"Ijichi","year":"2002","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.ctrv.2025.102908_b0155","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1245\/s10434-009-0622-2","article-title":"Clinical and prognostic significance of urinary trypsin inhibitor in patients with hepatocellular carcinoma after hepatectomy","volume":"16","author":"Kikuchi","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0160","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6690095","article-title":"Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma","volume":"79","author":"Saffroy","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0165","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1781::AID-CNCR4>3.0.CO;2-F","article-title":"Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma","volume":"77","author":"Aoyagi","year":"1996","journal-title":"Cancer"},{"issue":"135","key":"10.1016\/j.ctrv.2025.102908_b0170","first-page":"213","article-title":"Detection of isolated disseminated tumor cells in bone marrow and blood samples of patients with hepatocellular carcinoma","volume":"2000","author":"Kienle","year":"1960","journal-title":"Arch Surg Chic Ill"},{"key":"10.1016\/j.ctrv.2025.102908_b0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3748\/wjg.v10.i1.31","article-title":"Does surgical resection of hepatocellular carcinoma accelerate cancer dissemination?","volume":"10","author":"Sheen","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2025.102908_b0180","first-page":"3516","article-title":"Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients","volume":"6","author":"Wong","year":"2000","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s005340050103","article-title":"Measurement of serum circulating intercellular adhesion molecule-1 and its clinical significance in hepatocellular carcinoma: preliminary report","volume":"6","author":"Mei","year":"1999","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.ctrv.2025.102908_b0190","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/1097-0142(19880415)61:8<1621::AID-CNCR2820610820>3.0.CO;2-C","article-title":"Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma","volume":"61","author":"Fujiyama","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0195","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0168-8278(99)80232-3","article-title":"Presence of alpha-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma","volume":"31","author":"Matsumura","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2025.102908_b0200","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1067\/msy.2002.118954","article-title":"Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma","volume":"131","author":"Witzigmann","year":"2002","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2025.102908_b0205","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s004230000199","article-title":"Quantification of alpha 1-fetoprotein mRNA in peripheral blood and bone marrow: a tool for perioperative evaluation of patients with hepatocellular carcinoma","volume":"386","author":"Aselmann","year":"2001","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.ctrv.2025.102908_b0210","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cdp.2005.12.003","article-title":"Quantitation of alpha-fetoprotein messenger RNA for early detection of recurrent hepatocellular carcinoma: a prospective pilot study","volume":"30","author":"Schmilovitz-Weiss","year":"2006","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.ctrv.2025.102908_b0215","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/(SICI)1098-2388(199605\/06)12:3<160::AID-SSU3>3.0.CO;2-5","article-title":"Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma","volume":"12","author":"Nakao","year":"1996","journal-title":"Semin Surg Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2025.102908_b0220","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000345892","article-title":"Biomarker studies on radiotherapy to hepatocellular carcinoma","volume":"84","author":"Tsai","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2025.102908_b0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13277-013-1141-0","article-title":"Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med"},{"key":"10.1016\/j.ctrv.2025.102908_b0230","doi-asserted-by":"crossref","first-page":"13073","DOI":"10.3390\/ijms222313073","article-title":"Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal","volume":"22","author":"Espejo-Cruz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.102908_b0235","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/jpm14040420","article-title":"Clinical Application of Different Liquid Biopsy Components in Hepatocellular Carcinoma","volume":"14","author":"Xu","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.ctrv.2025.102908_b0240","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.31165","article-title":"Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma","volume":"73","author":"Ahn","year":"2021","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.ctrv.2025.102908_b0245","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12029-016-9801-0","article-title":"Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma","volume":"47","author":"Zhou","year":"2016","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0250","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12943-019-1043-x","article-title":"Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA","volume":"18","author":"Ye","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0255","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-023-11711-7","article-title":"Prognostic value of circulating tumor cells associated with white blood cells in solid cancer: a systematic review and meta-analysis of 1471 patients with solid tumors","volume":"23","author":"Ju","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0260","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00432-004-0572-9","article-title":"Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature","volume":"130","author":"Qin","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0265","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3748\/wjg.v8.i2.193","article-title":"The prognostic significance of clinical and pathological features in hepatocellular carcinoma","volume":"8","author":"Qin","year":"2002","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2025.102908_b0270","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.3390\/ijms24054286","article-title":"Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review","volume":"24","author":"Shahini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.102908_b0275","first-page":"2879","article-title":"Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review","volume":"18","author":"Chen","year":"2020","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.ctrv.2025.102908_b0280","doi-asserted-by":"crossref","unstructured":"Chen VL, Xu D, Harouaka R, Wicha M, Lounsk A, Parikh ND. Mo1451 \u2013 Liquid Biopsy for Prognosis in Hepatocellular Carcinoma (HCC) Using Circulating Tumor Cells (CTCS): A Systematic Review and Meta-Analysis. Gastroenterology 2019;156:S-1311. DOI: 10.1016\/S0016-5085(19)40292-8.","DOI":"10.1016\/S0016-5085(19)40292-8"},{"key":"10.1016\/j.ctrv.2025.102908_b0285","doi-asserted-by":"crossref","first-page":"861","DOI":"10.11569\/wcjd.v18.i9.861","article-title":"Effects of hepatic ischemia\/reperfusion injury on tumor proliferation and metastasis","volume":"18","author":"Zhou","year":"2010","journal-title":"World Chin J Dig"},{"key":"10.1016\/j.ctrv.2025.102908_b0290","doi-asserted-by":"crossref","first-page":"404","DOI":"10.11569\/wcjd.v31.i10.404","article-title":"Circulating biomarkers for diagnosis and management of hepatocellular carcinoma","volume":"31","author":"Xu","year":"2023","journal-title":"World Chin J Dig"},{"key":"10.1016\/j.ctrv.2025.102908_b0295","first-page":"946","article-title":"A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma","volume":"24","author":"Court","year":"2018","journal-title":"Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"key":"10.1016\/j.ctrv.2025.102908_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246527","article-title":"Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments in patients with hepatocellular carcinoma","volume":"16","author":"Vogl","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.102908_b0305","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/MEG.0000000000001373","article-title":"Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA","volume":"31","author":"Li","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2025.102908_b0310","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.510250312","article-title":"Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver","volume":"25","author":"Funaki","year":"1997","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.ctrv.2025.102908_b0320","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jvir.2013.10.030","article-title":"Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres","volume":"25","author":"Carpizo","year":"2014","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"10.1016\/j.ctrv.2025.102908_b0325","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2017.10.004","article-title":"Quantified postsurgical small cell size CTCs and EpCAM+ circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse","volume":"412","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2025.102908_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2019.120402","article-title":"Rapid detection of hepatocellular carcinoma metastasis using reverse transcription loop-mediated isothermal amplification","volume":"208","author":"Yao","year":"2020","journal-title":"Talanta"},{"key":"10.1016\/j.ctrv.2025.102908_b0335","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12967-015-0743-2","article-title":"HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma","volume":"13","author":"Xue","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2025.102908_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.101445","article-title":"Investigating the Influence of Preoperative Trans Arterial Embolization (TAE) and Predictive Potential of Circulating Tumor Cells (CTCs) in Prognosis of Hepatocellular Carcinoma","volume":"14","author":"Patkar","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.ctrv.2025.102908_b0345","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1538-7445.AM2023-1020","article-title":"Abstract 1020: Tissue-informed ctDNA MRD assay detects post-surgery minimal residual disease in HCC patients","volume":"83","author":"Hu","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0350","doi-asserted-by":"crossref","unstructured":"Abstracts of the 26th Annual Conference of APASL, February 15\u201319, 2017, Shanghai, China. Hepatol Int 2017;11:1\u20131093. DOI: 10.1007\/s12072-016-9783-9.","DOI":"10.1007\/s12072-016-9783-9"},{"key":"10.1016\/j.ctrv.2025.102908_b0360","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.dld.2015.12.061","article-title":"Circulating microRNA in hepatocellular carcinoma as prognostic biomarkers","volume":"48","author":"Pascut","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ctrv.2025.102908_b0365","doi-asserted-by":"crossref","unstructured":"Juratli M, Oppermann E, Pascher A, Bechstein W, Vogl T. Dynamic of circulating tumor cells in hepatocellular carcinoma under interventional radiological treatment, M\u00fcnster: 2021, p. s-0040-1722000. DOI: 10.1055\/s-0040-1722000.","DOI":"10.1055\/s-0040-1722000"},{"key":"10.1016\/j.ctrv.2025.102908_b0370","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1016\/j.hpb.2023.07.045","article-title":"Effect of Pre-operative Trans-Arterial Embolisation (TAE) on Circulating Tumor Cells and Recurrence in Hepatocellular Carcinoma","volume":"25","author":"Goel","year":"2023","journal-title":"HPB"},{"key":"10.1016\/j.ctrv.2025.102908_b0375","first-page":"S308","article-title":"P-165 The feasibility of tumor recurrence detection in liver post-transplantation for patients with hepatocellular carcinoma via personalized, tumor-informed ctDNA testing","volume":"33","author":"Abdelrahim","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0380","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S0618-8278(19)30707-8","article-title":"THU-460-Longitudinal monitoring of cell-free DNA predicts for transarterial chemo-embolization failure in hepatocellular carcinoma","volume":"70","author":"Evans","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102908_b0385","first-page":"A1","article-title":"Oral Presentations. United Eur","volume":"2016","author":"Week","year":"2016","journal-title":"Gastroenterol J"},{"key":"10.1016\/j.ctrv.2025.102908_b0901","unstructured":"Ng K.T.-P.,Lam L.Y.-F.,Li C.X.,Qi X.,Yeung O.W.-H.,Liu H.,Liu J.,Lo C.M.,Man K. Up-regulation of GSTA2 at early-phase after liver transplantation increases the risk of late-phase hepatocellular carcinoma recurrence. Transplantation 2016 100:7 (S425-S426) Supplement 1. 10.1097\/01.tp.0000490147.72544.1a."},{"key":"10.1016\/j.ctrv.2025.102908_b0390","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1111\/ajt.15490","article-title":"Circulating exosomal miR-92b: Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence","volume":"19","author":"Nakano","year":"2019","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"10.1016\/j.ctrv.2025.102908_b0395","doi-asserted-by":"crossref","first-page":"19824","DOI":"10.18632\/oncotarget.7627","article-title":"Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation","volume":"7","author":"Ng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.102908_b0400","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1158\/0008-5472.CAN-11-3733","article-title":"Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis","volume":"72","author":"Fan","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0405","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/labinvest.2012.65","article-title":"Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts","volume":"92","author":"Martin-Padura","year":"2012","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"10.1016\/j.ctrv.2025.102908_b0410","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.7150\/thno.16023","article-title":"The Clinical Significance and Potential Therapeutic Role of GPx3 in Tumor Recurrence after Liver Transplantation","volume":"6","author":"Qi","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.ctrv.2025.102908_b0415","doi-asserted-by":"crossref","unstructured":"Abstracts. Transplantation 2016;100:S77\u2013262. DOI: 10.1097\/01.tp.0000483259.57907.d4.","DOI":"10.1097\/01.tp.0000483259.57907.d4"},{"key":"10.1016\/j.ctrv.2025.102908_b0420","doi-asserted-by":"crossref","unstructured":"&Na; Poster Sessions: Translational. Transplantation 2014;98:871\u2013905. DOI: 10.1097\/01.tp.0000452138.48155.71.","DOI":"10.1097\/01.tp.0000452138.48155.71"},{"key":"10.1016\/j.ctrv.2025.102908_b0425","doi-asserted-by":"crossref","unstructured":"The 2011 Joint International Congress of ILTS, ELITA, and LICAGE. Liver Transpl 2011;17:S1\u2013324. DOI: 10.1002\/lt.22457.","DOI":"10.1002\/lt.22457"},{"key":"10.1016\/j.ctrv.2025.102908_b0902","first-page":"133","article-title":"Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation","volume":"42","author":"Shi","year":"2023","journal-title":"J Exp Clin Cancer Res CR"},{"key":"10.1016\/j.ctrv.2025.102908_b0903","unstructured":"Nakano T.,Chen I.-H.,Goto S.,Lai C.-Y.,Tseng H.-P.,Kuo I.-Y.,Lin C.-C.,Chiu K.-W.,Cheng Y.-F.,Chen C.-L. Impact of circulating exosomes on the development and recurrence of hepatocellular carcinoma in rats. Transplantation 2016 100:7 (S481) Supplement 1. 10.1097\/01.tp.0000490147.72544.1a."},{"key":"10.1016\/j.ctrv.2025.102908_b0430","first-page":"72","article-title":"Haptocorrin as marker of disease progression in fibrolamellar hepatocellular carcinoma","volume":"37","author":"Lildballe","year":"2011","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0435","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760765","article-title":"Measurement of Circulating Tumor Cells to Track Hepatocellular Carcinoma Progression After Liver Transplantation-Case Report","volume":"11","author":"Deng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0904","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.suronc.2020.08.024","article-title":"K.-W.,Kim H.-C.,Yi N.-J.,Suh K.-S. No touch isolation technique for the prevention of postoperative recurrence of hepatocellular carcinoma after liver transplantation-combined with trans-arterial radioembolization","volume":"35","author":"Lee","year":"2020","journal-title":"Surgical Oncology"},{"key":"10.1016\/j.ctrv.2025.102908_b0445","first-page":"383","article-title":"Effect of CD133-positive stem cells in repeated recurrence of hepatocellular carcinoma after liver transplantation: a case report","volume":"104","author":"Toshima","year":"2013","journal-title":"Fukuoka Igaku Zasshi Hukuoka Acta Medica"},{"key":"10.1016\/j.ctrv.2025.102908_b0450","first-page":"118","article-title":"The clinical value of heat shock protein 90\u03b1 in predicting the prognosis of interventional therapy for hepatocellular carcinoma","volume":"46","author":"Sun","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.ctrv.2025.102908_b0455","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/hep.31230","article-title":"Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer","volume":"72","author":"Li","year":"2020","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.ctrv.2025.102908_b0460","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ijc.33829","article-title":"Circulating DNA changes are predictive of disease progression after transarterial chemoembolization","volume":"150","author":"Sefrioui","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0465","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1158\/1078-0432.CCR-18-3477","article-title":"Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma","volume":"25","author":"Cai","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0470","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/1878-0261.13170","article-title":"Copy number profiling of circulating free DNA predicts transarterial chemoembolization response in advanced hepatocellular carcinoma","volume":"16","author":"Dong","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0475","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/1878-0261.13498","article-title":"Identification of tumor mutations in plasma based on mutation variant frequency change (MVFC)","volume":"17","author":"Chen","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100021","article-title":"Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma","volume":"6","author":"Cai","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2025.102908_b0485","article-title":"Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection","volume":"13","author":"Xu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0490","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12072-023-10594-x","article-title":"Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer","volume":"18","author":"Huang","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ctrv.2025.102908_b0495","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/1878-0261.13105","article-title":"Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study","volume":"16","author":"Zhu","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0500","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/00365521.2020.1839127","article-title":"The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma","volume":"55","author":"Long","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ctrv.2025.102908_b0505","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2024-331956","article-title":"Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments","author":"Campani","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2025.102908_b0510","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/SLA.0000000000006386","article-title":"Tumor Mutational Burden From Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection: An Emerging Biomarker for Surveillance","volume":"280","author":"Wehrle","year":"2024","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2025.102908_b0515","article-title":"Personalized MRD Assessment in Peri-surgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma","author":"Hu","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0520","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.annonc.2024.05.190","article-title":"181P Circulating tumor DNA (ctDNA) testing for recurrence and treatment response monitoring in hepatocellular carcinoma (HCC)","volume":"35","author":"Abdelrahim","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0525","doi-asserted-by":"crossref","first-page":"S661","DOI":"10.1016\/j.annonc.2024.08.1018","article-title":"958P Utilizing personalized tumor-specific methylation haplotypes of circulating tumor DNA for monitoring minimal residual disease in hepatocellular carcinoma patients after curative resection","volume":"35","author":"Yang","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0530","doi-asserted-by":"crossref","first-page":"S698","DOI":"10.1016\/j.annonc.2020.08.1123","article-title":"1007P cfDNA and ctDNA variations are predictive of disease progression to conventional transarterial chemoembolization (cTACE) in patients with hepatocellular carcinoma (HCC)","volume":"31","author":"Sefrioui","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0535","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1158\/1538-7445.AM2022-5118","article-title":"Abstract 5118: Postoperative minimal residual disease to predict the risk of hepatocellular carcinoma (HCC) recurrence using plasma-only circulating tumor DNA assay","volume":"82","author":"Pan","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0540","doi-asserted-by":"crossref","first-page":"e16149","DOI":"10.1200\/JCO.2022.40.16_suppl.e16149","article-title":"Application of circulating tumor DNA for prediction and surveillance of tumor recurrence after liver transplantation: A pilot study","volume":"40","author":"Huang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0545","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.ijrobp.2017.06.216","article-title":"Cell-Free DNA as a Predictive Marker After Radiation Therapy for Hepatocellular Carcinoma","volume":"99","author":"Park","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0550","doi-asserted-by":"crossref","first-page":"S605","DOI":"10.1016\/j.hpb.2024.04.025","article-title":"Circulating tumor DNA monitoring for recurrence detection and treatment response assessment in HCC","volume":"26","author":"Abdelrahim","year":"2024","journal-title":"HPB"},{"key":"10.1016\/j.ctrv.2025.102908_b0555","doi-asserted-by":"crossref","first-page":"e16146","DOI":"10.1200\/JCO.2018.36.15_suppl.e16146","article-title":"Detection of early recurrence in HCC patients after TACE treatment with plasma cfDNA","volume":"36","author":"Du","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0560","doi-asserted-by":"crossref","first-page":"e14544","DOI":"10.1200\/JCO.2019.37.15_suppl.e14544","article-title":"Longitudinal monitoring of cell-free DNA to predict for transarterial chemo-embolization failure in hepatocellular carcinoma","volume":"37","author":"Evans","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0565","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1200\/JCO.2020.38.15_suppl.4593","article-title":"Perioperative circulating tumor DNA analysis to predict patient prognosis in liver cancer","volume":"38","author":"Zhou","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0570","author":"Chen","year":"2024","journal-title":"Plasma cell-free DNA methylomes for hepatocellular carcinoma detection and monitoring after liver resection or transplantation"},{"key":"10.1016\/j.ctrv.2025.102908_b0575","first-page":"1","article-title":"Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation","volume":"66","author":"Wang","year":"2018","journal-title":"J Investig Med Off Publ Am Fed Clin Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0580","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.asjsur.2021.07.058","article-title":"Association of phenotypic transformation of circulating tumor cells and early recurrence in patients with hepatocellular carcinoma following liver transplantation","volume":"45","author":"Xie","year":"2022","journal-title":"Asian J Surg"},{"key":"10.1016\/j.ctrv.2025.102908_b0585","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5009\/gnl210162","article-title":"Circulating Cancer Stem Cells Expressing EpCAM\/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation","volume":"16","author":"Hwang","year":"2022","journal-title":"Gut Liver"},{"key":"10.1016\/j.ctrv.2025.102908_b0590","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/hep.26151","article-title":"Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection","volume":"57","author":"Sun","year":"2013","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.ctrv.2025.102908_b0595","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s12072-019-09994-9","article-title":"Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study","volume":"13","author":"Ha","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ctrv.2025.102908_b0600","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1038\/s41598-019-43572-1","article-title":"Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2025.102908_b0605","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-17-2459","article-title":"Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma","volume":"78","author":"Qi","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0610","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-17-1753","article-title":"Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0615","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11605-017-3619-3","article-title":"Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood","volume":"22","author":"Wang","year":"2018","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract"},{"key":"10.1016\/j.ctrv.2025.102908_b0620","first-page":"562","article-title":"Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation","volume":"41","author":"Wang","year":"2021","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.ctrv.2025.102908_b0625","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1186\/s12885-018-4744-4","article-title":"Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma","volume":"18","author":"Yu","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0630","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/cncy.22304","article-title":"Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection","volume":"128","author":"Sun","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.ctrv.2025.102908_b0635","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1186\/s12885-020-07488-8","article-title":"Preoperative circulating tumor cells to predict microvascular invasion and dynamical detection indicate the prognosis of hepatocellular carcinoma","volume":"20","author":"Zhou","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0640","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1007\/s00432-022-04526-9","article-title":"The mesenchymal circulating tumor cells as biomarker for prognosis prediction and supervision in hepatocellular carcinoma","volume":"149","author":"Zhao","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0645","doi-asserted-by":"crossref","unstructured":"9th Asia-Pacific Primary Liver Cancer Expert Meeting, Seoul, South Korea, July 6-8, 2018. Liver Cancer 2018;7:1\u2013224. DOI: 10.1159\/000490877.","DOI":"10.1159\/000490877"},{"key":"10.1016\/j.ctrv.2025.102908_b0650","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.hpb.2020.11.248","article-title":"Circulating Cancer Stem Cells in Hepatocellular Carcinoma: A Pilot Study of Prediction for Tumor Recurrence after Living Donor Liver Transplantation","volume":"23","author":"Hwang","year":"2021","journal-title":"HPB"},{"key":"10.1016\/j.ctrv.2025.102908_b0655","doi-asserted-by":"crossref","unstructured":"Juratli M, Oppermann E, Schnitzbauer A, Pascher A, Bechstein W. Detection of PD-L1(+)Circulating Tumor Cells Significantly Correlates with Postoperative Recurrence in HCC Patients, M\u00fcnster: 2021, p. s-0040-1721986. DOI: 10.1055\/s-0040-1721986.","DOI":"10.1055\/s-0040-1721986"},{"key":"10.1016\/j.ctrv.2025.102908_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106385","article-title":"Liquid biopsy for hepatocellular carcinoma: Preliminary results on the association between postoperative early recurrence and the expression pattern of circulating tumor cells","volume":"100","author":"Ciulli","year":"2022","journal-title":"Int J Surg"},{"key":"10.1016\/j.ctrv.2025.102908_b0665","doi-asserted-by":"crossref","unstructured":"Guo D, Zhang S, Yang M, Xu Y, Wang P, Guo W, et al. Postoperative circulating tumor cells predict the benefits of tyrosine kinase inhibitor for hepatocellular carcinoma after transplantation. Hepatol Res 2025:hepr.14154. DOI: 10.1111\/hepr.14154.","DOI":"10.1111\/hepr.14154"},{"key":"10.1016\/j.ctrv.2025.102908_b0905","doi-asserted-by":"crossref","unstructured":"Fu B.,Yang Q.,Tang H.,Zhang Y.,Zhang X.,Xie Y.,Yi S.,Yang Y.,Chen G. Correlation between classification of circulating tumor cells in peripheral blood and early recurrence in patients with hepatocellular carcinoma after liver transplantation. Transplantation 2019 103:8 (311) Supplement 1. 10.1097\/01.tp.0000580472.17422.db.","DOI":"10.1016\/S0618-8278(19)31110-7"},{"key":"10.1016\/j.ctrv.2025.102908_b0670","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1007\/s13277-015-4340-z","article-title":"Circulating miR-148\/152 family as potential biomarkers in hepatocellular carcinoma","volume":"37","author":"Wang","year":"2016","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med"},{"issue":"Suppl 3","key":"10.1016\/j.ctrv.2025.102908_b0675","doi-asserted-by":"crossref","first-page":"S1444","DOI":"10.1245\/s10434-015-4480-9","article-title":"Increased Expression of Circulating Cancer Stem Cell Markers During the Perioperative Period Predicts Early Recurrence After Curative Resection of Hepatocellular Carcinoma","volume":"22","author":"Choi","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0680","doi-asserted-by":"crossref","first-page":"7908","DOI":"10.3390\/ijms24097908","article-title":"Overexpression of miR-4669 Enhances Tumor Aggressiveness and Generates an Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma: Its Clinical Value as a Predictive Biomarker","volume":"24","author":"Nakano","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.102908_b0685","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1590-8658(20)30537-5","article-title":"OC.05.1 MICRORNA-21 AND MICRORNA-122: prognosis prediction and correlation with HIF-1ALPHA in hepatocellular carcinoma patients treated with transarterial chemoembolization","volume":"52","author":"Pelizzaro","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ctrv.2025.102908_b0690","first-page":"1","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2025.102908_b0695","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.7150\/jca.59612","article-title":"Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation","volume":"12","author":"Huang","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2025.102908_b0700","doi-asserted-by":"crossref","unstructured":"The ILTS 18th Annual International Congress. Liver Transpl 2012;18:S1\u2013306. DOI: 10.1002\/lt.23435.","DOI":"10.1002\/lt.23435"},{"key":"10.1016\/j.ctrv.2025.102908_b0705","doi-asserted-by":"crossref","unstructured":"Liver Cancer. Hepatology 2013;58:1213A-1276A. DOI: 10.1002\/hep.26883.","DOI":"10.1002\/hep.26883"},{"key":"10.1016\/j.ctrv.2025.102908_b0710","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-018-6402-0","article-title":"Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma","volume":"25","author":"Ma","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0715","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clinbiochem.2013.11.022","article-title":"Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization","volume":"47","author":"Daniele","year":"2014","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ctrv.2025.102908_b0720","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jvir.2023.01.032","article-title":"Correlation of Serum Chemokine Ligand 14 with Barcelona Clinic Liver Cancer Stage, Lymphocyte Profile, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma","volume":"34","author":"Guo","year":"2023","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"10.1016\/j.ctrv.2025.102908_b0725","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1155\/2013\/781740","article-title":"Expression and clinical significance of livin protein in hepatocellular carcinoma","volume":"35","author":"Guo","year":"2013","journal-title":"Dis Markers"},{"key":"10.1016\/j.ctrv.2025.102908_b0730","doi-asserted-by":"crossref","first-page":"37835","DOI":"10.18632\/oncotarget.14271","article-title":"Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma","volume":"8","author":"Ofuji","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.102908_b0735","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124943","article-title":"Repeated-measures implication of hepatocellular carcinoma biomarkers in living donor liver transplantation","volume":"10","author":"Chiu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.102908_b0740","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1021\/acs.jproteome.6b00833","article-title":"Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study","volume":"16","author":"Yu","year":"2017","journal-title":"J Proteome Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0745","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1499-3872(15)60403-9","article-title":"The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics","volume":"14","author":"Pan","year":"2015","journal-title":"Hepatobiliary Pancreat Dis Int HBPD INT"},{"key":"10.1016\/j.ctrv.2025.102908_b0750","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1515\/labmed-2021-0019","article-title":"Blood indices and circulating tumor cells for predicting metastasis of hepatocellular carcinoma after liver transplantation","volume":"46","author":"Zhuang","year":"2022","journal-title":"J Lab Med"},{"key":"10.1016\/j.ctrv.2025.102908_b0755","doi-asserted-by":"crossref","unstructured":"Adel N, Halima ASA, Samir Elbaz H, Hossam Eldin AFS. Correlation of Circulating Cathelcidin Level and Inflammatory Bowel Disease Activity. QJM Int J Med 2023;116:hcad069.360. DOI: 10.1093\/qjmed\/hcad069.360.","DOI":"10.1093\/qjmed\/hcad069.360"},{"key":"10.1016\/j.ctrv.2025.102908_b0760","doi-asserted-by":"crossref","unstructured":"Poster Session 1: Gene Expression and Therapy; Health Care Delivery\/Access\/Quality. Hepatology 2015;62:456A-497A. DOI: 10.1002\/hep.28213.","DOI":"10.1002\/hep.28213"},{"key":"10.1016\/j.ctrv.2025.102908_b0765","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1016\/j.hpb.2018.06.2661","article-title":"Prognostic role of HepPar1 positive circulating microparticles after hepatectomy for hepatocellular carcinoma","volume":"20","author":"Mele","year":"2018","journal-title":"HPB"},{"key":"10.1016\/j.ctrv.2025.102908_b0770","doi-asserted-by":"crossref","unstructured":"Roushansarai N, Oppermann E, Roy D, Schnitzbauer A, Houben P, Katou S, et al. Long-term dynamics of extracellular vesicles as recurrence markers in hepatocellular carcinoma patients following surgical tumor resection, Erst online. Dann Hamburg.: 2023, p. s-0043-1772094. DOI: 10.1055\/s-0043-1772094.","DOI":"10.1055\/s-0043-1772094"},{"key":"10.1016\/j.ctrv.2025.102908_b0775","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231190644","article-title":"Dynamic Changes of Cytokine Profiles and Their Correlation With Tumor Recurrence Following Thermal Ablation in Hepatocellular Carcinoma","volume":"22","author":"Guo","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2025.102908_b0780","article-title":"Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study","volume":"8","author":"Liao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.102908_b0785","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.hbpd.2023.10.006","article-title":"Indications of pro-inflammatory cytokines in laparoscopic and open liver resection for early-stage hepatocellular carcinoma","volume":"23","author":"Ng","year":"2024","journal-title":"Hepatobiliary Pancreat Dis Int HBPD INT"},{"key":"10.1016\/j.ctrv.2025.102908_b0790","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1440-1746.2011.06910.x","article-title":"Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation","volume":"27","author":"Chen","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 185","key":"10.1016\/j.ctrv.2025.102908_b0795","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ijcp.12811","article-title":"Peripheral blood CD4(+) cell ATP activity measurement to predict HCC recurrence post-DCD liver transplant","volume":"70","author":"Zhang","year":"2016","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ctrv.2025.102908_b0800","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3748\/wjg.v23.i11.2077","article-title":"Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy","volume":"23","author":"Cha","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2025.102908_b0805","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.ijrobp.2019.06.607","article-title":"Determining and Incorporating the Optimal Predictive Biomarkers in Hepatocellular Carcinoma Patients Treated with Radiotherapy","volume":"105","author":"Chung","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0810","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ijrobp.2020.07.2243","article-title":"Increased Serum Type I Interferon Level May Predict Outcome in Hepatocellular Carcinoma Patients Treated with Radiotherapy","volume":"108","author":"Du","year":"2020","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0815","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.ijrobp.2017.06.214","article-title":"The Clinical Implications of Soluble PD-L1 in Hepatocellular Carcinoma Patients Treated With Radiation Therapy","volume":"99","author":"Kim","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0820","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1158\/2159-8290.CD-21-1252","article-title":"The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer","volume":"13","author":"Mattox","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2025.102908_b0825","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3748\/wjg.v12.i8.1175","article-title":"Serum tumor markers for detection of hepatocellular carcinoma","volume":"12","author":"Zhou","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2025.102908_b0830","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.102908_b0835","doi-asserted-by":"crossref","unstructured":"Lonardi S, Montagut C, Pietrantonio F, Elez E, Sartore-Bianchi A, Tarazona N, et al. The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. J Clin Oncol 2020;38:TPS4124\u2013TPS4124. DOI: 10.1200\/JCO.2020.38.15_suppl.TPS4124.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4124"},{"key":"10.1016\/j.ctrv.2025.102908_b0840","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102908_b0845","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/j.annonc.2024.08.234","article-title":"293P Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq","volume":"35","author":"Cabel","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0850","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1078-0432.CCR-23-2326","article-title":"Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer","volume":"30","author":"Coakley","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102908_b0855","doi-asserted-by":"crossref","unstructured":"Lencioni R, Kudo M, Erinjeri J, Qin S, Ren Z, Chan S, et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J Clin Oncol 2024;42:LBA432\u2013LBA432. DOI: 10.1200\/JCO.2024.42.3_suppl.LBA432.","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA432"},{"key":"10.1016\/j.ctrv.2025.102908_b0860","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","article-title":"Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.102908_b0865","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0870","doi-asserted-by":"crossref","first-page":"S1230","DOI":"10.1016\/j.annonc.2024.08.2279","article-title":"LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)","volume":"35","author":"Yopp","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0875","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ctrv.2025.102908_b0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103112","article-title":"International liquid biopsy standardization alliance white paper","volume":"156","author":"Connors","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2025.102908_b0885","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ajt.15697","article-title":"Liver transplantation for hepatocellular carcinoma: Management after the transplant","volume":"20","author":"Verna","year":"2020","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"10.1016\/j.ctrv.2025.102908_b0890","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2016.5116","article-title":"Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant","volume":"3","author":"Mehta","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.102908_b0895","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/jnci\/djae079","article-title":"Prediagnostic plasma proteomics profile for hepatocellular carcinoma","volume":"116","author":"Zhang","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2025.102908_b0900","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ajpath.2024.02.017","article-title":"Serum fusion transcripts to assess the risk of hepatocellular carcinoma and the impact of cancer treatment through machine learning","volume":"194","author":"Yu","year":"2024","journal-title":"Am J Pathol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T03:04:05Z","timestamp":1763521445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":182,"alternative-id":["S0305737225000301"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102908","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102908"}}